Innovent Biologics Inc/ADR
IVBXFDrugs in Pipeline
54
Phase 3 Programs
28
Upcoming Catalysts
20
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
20 upcoming, 1 past
Docetaxel
HER2-positive Breast Cancer
Aflibercept Ophthalmic
Neovascular Age-related Macular Degeneration
IBI354
Locally Advanced Unresectable or Metastatic Solid Tumors
Pemetrexed
Non-Small Cell Lung Cancer
IBI303
AS
Gemcitabine
Squamous NSCLC
IBI311
Thyroid Eye Disease
Sorafenib
Hepatocellular Carcinoma
Irinotecan OR Paclitaxel or Trifluridine/tipiracil（ FTD/TPI）
Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
IBI308
Esophageal Squamous Cell Carcinoma
paclitaxel/Gemcitabine/Liposomal doxorubicin
Ovarian
Platinum
Lung Neoplasms
Febuxostat
Gout
IBI112
Psoriasis
semaglutide
Overweight
IBI305
Non-Squamous Non-Small Cell Lung Cancer
IBI343
Pancreatic Cancer
IBI310
Advanced Cervical Cancer
Sintilimab
Esophageal Squamous Cell Carcinoma
IBI362
Type 2 Diabetes
IBI305 in Combination with Paclitaxel/Carboplatin
NSCLC
Oxaliplatin
Gastric Cancer
IBI301 plus CHOP
Diffuse, Large B-Cell, Lymphoma
IBI310&Sintilimab
MSI-H
dulaglutide
Type 2 Diabetes
Picankibart
Plaque Psoriasis
IBI306 450mg SC Q4W
Hypercholesterolemia
IBI306
Homozygous Familial Hypercholesterolemia
GFH925
KRAS G12C
IBI311 (20 mg)
Thyroid Eye Disease
Low dose IBI302
Neovascular Age-related Macular Degeneration
IBI3003
Multiple Myeloma
Tirzepatide
Obesity
IBI112 dose 2
Psoriasis
PD1
Relapsed/Refractory Classical Hodgkin's Lymphoma
IBI376
Indolent Non-hodgkin Lymphoma
IBI363
Melanoma
IBI334
Advanced Solid Tumors
IBI130
Solid Tumor
IBI129
Solid Tumor
IBI343,sintilimab,oxaliplatin,S-1
CLDN18.2 Positive
IBI302 8mg dose
Neovascular Age-related Macular Degeneration
Dupilumab
Atopic Dermatitis
regular treatment
Psoriasis
IBI343,Gemcitabine, Albumin-bound Paclitaxel
CLDN18.2 Positive
IBI128
Gout
Pemigatinib
Cholangiocarcinoma
Cisplatin
Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
IBI3014
Unresectable Locally Advanced or Metastatic Solid Tumors
IBI133
Locally Advanced Unresectable or Metastatic Solid Tumors
IBI3002
Atopic Dermatitis
IBI302
Diabetic Macular Oedema
dose 1 IBI302
Neovascular Age-related Macular Degeneration
Period 2 IBI112 dose 3
Ulcerative Colitis (UC)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Docetaxel | Phase 3 | HER2-positive Breast Cancer | - | - |
Aflibercept Ophthalmic | Phase 3 | Neovascular Age-related Macular Degeneration | - | - |
IBI354 | Phase 3 | Locally Advanced Unresectable or Metastatic Solid Tumors | - | - |
Pemetrexed | Phase 3 | Non-Small Cell Lung Cancer | - | - |
IBI303 | Phase 3 | AS | - | - |
Gemcitabine | Phase 3 | Squamous NSCLC | - | - |
IBI311 | Phase 3 | Thyroid Eye Disease | - | - |
Sorafenib | Phase 3 | Hepatocellular Carcinoma | - | - |
Irinotecan OR Paclitaxel or Trifluridine/tipiracil（ FTD/TPI） | Phase 3 | Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | - | - |
IBI308 | Phase 3 | Esophageal Squamous Cell Carcinoma | - | - |
paclitaxel/Gemcitabine/Liposomal doxorubicin | Phase 3 | Ovarian | - | - |
Platinum | Phase 3 | Lung Neoplasms | - | - |
Febuxostat | Phase 3 | Gout | - | - |
IBI112 | Phase 3 | Psoriasis | - | - |
semaglutide | Phase 3 | Overweight | - | - |
IBI305 | Phase 3 | Non-Squamous Non-Small Cell Lung Cancer | - | - |
IBI343 | Phase 3 | Pancreatic Cancer | - | - |
IBI310 | Phase 3 | Advanced Cervical Cancer | - | - |
Sintilimab | Phase 3 | Esophageal Squamous Cell Carcinoma | - | - |
IBI362 | Phase 3 | Type 2 Diabetes | - | - |
IBI305 in Combination with Paclitaxel/Carboplatin | Phase 3 | NSCLC | - | - |
Oxaliplatin | Phase 3 | Gastric Cancer | - | - |
IBI301 plus CHOP | Phase 3 | Diffuse, Large B-Cell, Lymphoma | - | - |
IBI310&Sintilimab | Phase 3 | MSI-H | - | - |
dulaglutide | Phase 3 | Type 2 Diabetes | - | - |
Picankibart | Phase 3 | Plaque Psoriasis | - | - |
IBI306 450mg SC Q4W | Phase 3 | Hypercholesterolemia | - | - |
IBI306 | Phase 3 | Homozygous Familial Hypercholesterolemia | - | - |
GFH925 | Phase 2 | KRAS G12C | - | - |
IBI311 (20 mg) | Phase 2 | Thyroid Eye Disease | - | - |
Low dose IBI302 | Phase 2 | Neovascular Age-related Macular Degeneration | - | - |
IBI3003 | Phase 2 | Multiple Myeloma | - | - |
Tirzepatide | Phase 2 | Obesity | - | - |
IBI112 dose 2 | Phase 2 | Psoriasis | - | - |
PD1 | Phase 2 | Relapsed/Refractory Classical Hodgkin's Lymphoma | - | - |
IBI376 | Phase 2 | Indolent Non-hodgkin Lymphoma | - | - |
IBI363 | Phase 2 | Melanoma | - | - |
IBI334 | Phase 2 | Advanced Solid Tumors | - | - |
IBI130 | Phase 2 | Solid Tumor | - | - |
IBI129 | Phase 2 | Solid Tumor | - | - |
IBI343,sintilimab,oxaliplatin,S-1 | Phase 2 | CLDN18.2 Positive | - | - |
IBI302 8mg dose | Phase 2 | Neovascular Age-related Macular Degeneration | - | - |
Dupilumab | Phase 2 | Atopic Dermatitis | - | - |
regular treatment | Phase 2 | Psoriasis | - | - |
IBI343,Gemcitabine, Albumin-bound Paclitaxel | Phase 2 | CLDN18.2 Positive | - | - |
IBI128 | Phase 2 | Gout | - | - |
Pemigatinib | Phase 2 | Cholangiocarcinoma | - | - |
Cisplatin | Phase 2 | Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer | - | - |
IBI3014 | Phase 2 | Unresectable Locally Advanced or Metastatic Solid Tumors | - | - |
IBI133 | Phase 2 | Locally Advanced Unresectable or Metastatic Solid Tumors | - | - |
IBI3002 | Phase 2 | Atopic Dermatitis | - | - |
IBI302 | Phase 2 | Diabetic Macular Oedema | - | - |
dose 1 IBI302 | Phase 2 | Neovascular Age-related Macular Degeneration | - | - |
Period 2 IBI112 dose 3 | Phase 2 | Ulcerative Colitis (UC) | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Innovent Biologics Inc/ADR's drug pipeline?→
CatalystAlert tracks 54 drug candidates in Innovent Biologics Inc/ADR's (IVBXF) pipeline across Phase 3, Phase 2. Its lead program is Docetaxel (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Innovent Biologics Inc/ADR's next FDA catalyst?→
Innovent Biologics Inc/ADR's (IVBXF) next tracked catalyst is a Phase 2 expected June 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IVBXF biotech catalysts?→
Add IVBXF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Innovent Biologics Inc/ADR's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.